Atomoxetine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for atomoxetine hydrochloride and what is the scope of freedom to operate?
Atomoxetine hydrochloride
is the generic ingredient in two branded drugs marketed by Apotex, Aurobindo Pharma, Dr Reddys, Glenmark Pharms Ltd, Hetero Labs Ltd V, Strides Pharma, Teva Pharms Usa, Zydus Pharms Usa Inc, and Lilly, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.There are fifteen drug master file entries for atomoxetine hydrochloride. Nineteen suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for atomoxetine hydrochloride
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 9 |
| NDAs: | 9 |
| Drug Master File Entries: | 15 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 97 |
| Clinical Trials: | 185 |
| Patent Applications: | 2,969 |
| What excipients (inactive ingredients) are in atomoxetine hydrochloride? | atomoxetine hydrochloride excipients list |
| DailyMed Link: | atomoxetine hydrochloride at DailyMed |
Recent Clinical Trials for atomoxetine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Apnimed | Phase 3 |
| Bronx VA Medical Center | Phase 1 |
| Assiut University | N/A |
Generic filers with tentative approvals for ATOMOXETINE HYDROCHLORIDE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for atomoxetine hydrochloride
| Drug Class | Norepinephrine Reuptake Inhibitor |
| Mechanism of Action | Norepinephrine Uptake Inhibitors |
Medical Subject Heading (MeSH) Categories for atomoxetine hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for atomoxetine hydrochloride
Paragraph IV (Patent) Challenges for ATOMOXETINE HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| STRATTERA | Capsules | atomoxetine hydrochloride | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | 021411 | 10 | 2007-05-29 |
US Patents and Regulatory Information for atomoxetine hydrochloride
Expired US Patents for atomoxetine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-001 | Nov 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-004 | Nov 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-005 | Nov 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-008 | Feb 14, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-007 | Feb 14, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-006 | Nov 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-003 | Nov 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
